Related Experiment Videos
New developments in the diagnosis and management of cardiac allograft vasculopathy
M R Mehra1, H O Ventura, F W Smart
1Department of Cardiology, Ochsner Medical Institutions, New Orleans, LA 70121, USA.
Insights
Cardiac allograft vasculopathy is a major cause of death in heart transplant patients. Medications like calcium entry blockers may help slow its progression, offering hope for improved long-term outcomes.
Area of Science:
- Cardiology
- Transplantation Immunology
Background:
- Cardiac allograft vasculopathy (CAV), or cardiac transplant atherosclerosis, affects up to 45% of heart transplant recipients surviving over 1 year.
- CAV is a leading cause of late mortality in cardiac transplant recipients.
- CAV exhibits distinct pathological features compared to typical atherosclerosis, including concentric intimal hyperplasia and intact internal elastic lamina.
Purpose of the Study:
- To summarize the characteristics and management of cardiac allograft vasculopathy.
- To highlight diagnostic modalities for CAV.
- To discuss potential therapeutic strategies for delaying CAV progression.
Main Methods:
- Review of existing literature on cardiac allograft vasculopathy.
- Comparison of diagnostic techniques including intravascular ultrasound, coronary angioscopy, and coronary angiography.
- Analysis of current and emerging therapeutic interventions.
Main Results:
- Cardiac allograft vasculopathy presents differently from typical atherosclerosis, characterized by rapid progression and specific histological findings.
- Intravascular ultrasound and coronary angioscopy demonstrate higher sensitivity in diagnosing CAV than coronary angiography.
- Retransplantation offers limited success, and pharmacological interventions are under investigation.
Conclusions:
- Cardiac allograft vasculopathy remains a significant challenge in long-term heart transplant care.
- Early and accurate diagnosis using advanced imaging is crucial.
- Pharmacological agents, including calcium entry blockers and ACE inhibitors, show promise in mitigating CAV progression.
Abstract:
The major cause of late death in cardiac transplant recipients is cardiac allograft vasculopathy, also referred to as cardiac transplant atherosclerosis, which occurs in as many as 45% of transplant recipients who survive longer than 1 year. It differs from typical atherosclerosis in that intimal hyperplasia is concentric and diffuse, the internal elastic lamina remains intact, calcification is rare, and the disease tends to develop rapidly. Intravascular ultrasound and coronary angioscopy are more sensitive diagnostic measures of cardiac allograft vasculopathy than is coronary angiography. Although retransplantation at present seems to be the only definitive therapy for cardiac allograft vasculopathy, it has shown only fair results. Recent studies have suggested that calcium entry blockers and angiotensin-converting enzyme inhibitors may play a beneficial role in delaying the progression of cardiac allograft vasculopathy.